INTRODUCTION {#s1}
============

Female reproductive system cancer, which includes cervical cancer, endometrial cancer, and ovarian cancer, is a major threat to women\'s health. In fact, cervical cancer ranks third among all gynecologic cancers in the world \[[@R1]\], 65 new endometrial cancer cases occur annually per 100,000 women between the ages of 65 to 75 \[[@R2]\], and approximately 140,200 new ovarian cancer cases worldwide per year are recorded \[[@R3]\]. Elucidating the etiology of female reproductive system cancer and identifying at-risk populations may allow more effective early detection and perhaps even prevention.

The causes of these cancers remain poorly understood. Infection with oncogenic human papilloma virus (HPV) is a risk factor in tumorigenesis \[[@R4]\], but many HPV carriers do not develop cervical cancer, indicating that there must be other cancer risk factors, such as genetic and environmental factors. One possible genetic factor may be polymorphism in the gene encoding x-ray repair cross complementing 1 (XRCC1) protein. The gene is located on chromosome 19 (19q13.2), and the expressed protein is involved in the base excision repair (BER) pathway \[[@R5], [@R6]\], which helps correct errors during DNA replication and recombination as well as preserve genome integrity \[[@R7]\]. Functional single-nucleotide polymorphisms (SNPs) in *XRCC1* have been linked to development of esophageal squamous cell carcinoma \[[@R8]\], lung cancer \[[@R9]\], pancreatic cancer \[[@R10]\], breast cancer \[[@R11]\], colorectal cancer \[[@R12]\], and gastric cancer \[[@R13]\]. While more than 300 *XRCC1* SNPs have been described in the dbSNP database, three functional SNPs have been extensively studied, all of which cause amino acid substitutions in the encoded protein: rs25487 \[Arg399Gln\], rs1799782 \[Arg194Trp\] and rs25489 \[Arg280His\].

Associations between *XRCC1* SNPs and risk of female reproducitve system cancer are unclear, because the several molecular epidemiologic studies conducted so far have been inconclusive. This lack of clarity may reflect the relatively small statistical power in individual studies, as well as heterogeneity in genetic backgrounds of study participants. Therefore we performed this meta-analysis to comprehensively assess available evidence on the association between *XRCC1* polymorphism and risk of female reproductive system cancer.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

Systematic search of the PubMed, EMBASE and China National Knowledge Infrastructure (CNKI) databases identified 157 potentially relevant studies (Figure [1](#F1){ref-type="fig"}). Further screening allowed elimination of all but 31 studies, which were read in full. In the end, 26 case-control studies were included in this study (Table [1](#T1){ref-type="table"}): data on rs25487 were reported in 24 studies involving 4,265 cases and 5,495 controls; data on rs1799782 were reported in 15 studies involving 2,672 cases and 3,578 controls; and data on rs25489 were reported in 5 studies with 907 cases and 1,416 controls. The various ethnic groups involved in the studies were divided into two categories: Asian or Non-Asian, with the latter including Caucasian, Latino, and mixed.

![PRISMA flow diagram](oncotarget-08-28455-g001){#F1}

###### Characteristics of studies included in the meta-analysis

  First author                 Year   Country       Ethnicity   Cancer type   Sourcecon   Source of DNA               Genotyping method   Case   Control   HWEcon
  ---------------------------- ------ ------------- ----------- ------------- ----------- --------------------------- ------------------- ------ --------- --------
  ***rs25487 (Arg399Gln)***                                                                                                                                
  Sobczuk                      2012   Poland        Caucasian   Endometrial   HB          Blood                       PCR-RFLP            94     114       0.161
  Hosono                       2013   Japan         Asian       Endometrial   HB          Blood                       PCR-RFLP            91     261       0.681
  Romanowicz-Makowska          2013   Poland        Caucasian   Endometrial   HB          Cervical specimens          PCR-RFLP            150    150       0.992
  Cincin                       2012   Turkey        Caucasian   Endometrial   HB          Blood                       PCR-RFLP            104    158       0.396
  Samulak                      2011   Poland        Caucasian   Endometrial   HB          Cervical specimens          PCR-RFLP            456    300       0.505
  Malisic                      2015   Serbia        Caucasian   Ovarian       PB          Cervical specimens          PCR-RFLP            50     78        0
  Monteiro                     2014   Brazil        Mixed       Ovarian       HB          Blood                       PCR-RFLP            70     70        0.676
  Khokhrina                    2015   Russia        Caucasian   Ovarian       HB          Blood                       PCR-RFLP            104    298       0.908
  Fan                          2013   China         Asian       Cervical      HB          Blood                       MAMA-PCR            235    350       0
  Wang                         2009   USA           Latino      Cervical      PB          Blood                       Taqman              457    442       0.761
  Wu                           2003   Taiwan        Asian       Cervical      PB          Blood                       PCR-RFLP            100    196       0.531
  Settheetham-Ishida           2011   Thailand      Asian       Cervical      HB          Blood                       PCR-RFLP            111    118       0.539
  Huang                        2007   China         Asian       Cervical      HB          Blood                       MA-PCR              539    800       0.104
  Farkasova                    2008   Slovakia      Caucasian   Cervical      HB          Blood                       PCR-RFLP            18     30        0.179
  Djansugurova                 2013   Kazakhstan    Mixed       Cervical      HB          Blood, cervical specimens   PCR-RFLP            217    160       0
  Zhang                        2012   China         Asian       Cervical      HB          Blood                       SNPstream           80     177       0.538
  Barbisan                     2011   Argentine     Latino      Cervical      HB          Cervical specimens          PCR-RFLP            103    114       0.49
  Jiang                        2009   China         Asian       Cervical      HB          Blood                       PCR-RFLP            436    503       0.482
  Niwa                         2005   Japan         Asian       Cervical      HB          Buffy coat                  PCR-RFLP            131    320       0.088
  Xiao                         2010   China         Asian       Cervical      HB          Blood                       PCR-RFLP            162    183       0.116
  Roszak                       2011   Poland        Caucasian   Cervical      PB          Blood                       PCR-RFLP            189    308       0.371
  Ma                           2011   China         Asian       Cervical      HB          Blood                       PCR-RFLP            200    200       0.061
  Alsbeih                      2013   SaudiArabia   Asian       Cervical      HB          Blood                       Sequencing          100    100       0.04
  Bajpai                       2016   India         Indian      Cervical      PB          Blood, cervical specimens   PCR-RFLP            68     65        0.036
  ***rs1799782(Arg194Trp)***                                                                                                                               
  Michalska                    2015   Poland        Caucasian   Ovarian       HB          Cervical specimens          PCR-RFLP            720    720       0.053
  Monteiro                     2014   Brazil        Mixed       Ovarian       HB          Blood                       PCR-RFLP            70     70        0.69
  Khokhrina                    2012   Russia        Caucasian   Ovarian       HB          Blood                       PCR-RFLP            104    298       0.562
  Sobczuk                      2012   Poland        Caucasian   Endometrial   HB          Blood                       PCR-RFLP            94     114       0.588
  Hosono                       2013   Japan         Asian       Endometrial   HB          Blood                       PCR-RFLP            91     251       0.525
  Fan                          2013   China         Asian       Cervical      HB          Blood                       MAMA-PCR            235    350       0
  Wu                           2003   Taiwan        Asian       Cervical      PB          Blood                       PCR-RFLP            100    196       0.196
  Settheetham-Ishida           2011   Thailand      Asian       Cervical      HB          Blood                       PCR-RFLP            111    118       0.023
  Huang                        2007   China         Asian       Cervical      HB          Blood                       MA-PCR              539    800       0.731
  Farkasova                    2008   Slovakia      Caucasian   Cervical      HB          Blood                       PCR-RFLP            17     30        0.543
  Djansugurova                 2013   Kazakhstan    Mixed       Cervical      HB          Blood, cervical specimens   PCR-RFLP            217    160       0.001
  Zhang                        2012   China         Asian       Cervical      HB          Blood                       SNPstream           80     117       0.434
  Barbisan                     2011   Argentine     Latino      Cervical      HB          Cervical specimens          PCR-RFLP            103    114       0
  Wang                         2010   China         Asian       Cervical      HB          Blood                       PCR-RFLP            123    175       0.849
  Bajpai                       2016   India         Indian      Cervical      PB          Blood, cervical specimens   PCR-RFLP            68     65        0.001
  ***rs25489 (Arg280His)***                                                                                                                                
  Wu                           2003   Taiwan        Asian       Cervical      PB          Blood                       PCR-RFLP            100    196       0.071
  Huang                        2007   China         Asian       Cervical      HB          Blood                       MA-PCR              539    800       0.463
  Zhang                        2012   China         Asian       Cervical      HB          Blood                       SNPstream           80     177       0.494
  Wang                         2010   China         Asian       Cervical      HB          Blood                       PCR-RFLP            123    175       0.043
  Bajpai                       2016   India         Indian      Cervical      PB          Blood, cervical specimens   PCR-RFLP            65     68        0

Sourcecon: Source of control. HWEcon: Hardy--Weinberg equilibrium in controls. PB, population-based; HB, hospital-based.

Of the 24 studies related to rs25487, 16 focused on cervical cancer \[[@R14]--[@R29]\], 5 on endometrial cancer \[[@R30]--[@R34]\], and 3 on ovarian cancer \[[@R35]--[@R37]\]. The ethnic group was Asian in 11 studies and Non-Asian in the others. Of the 15 studies related to rs1799782, 10 focused on cervical cancer \[[@R16]--[@R20], [@R25], [@R27], [@R28]\], 3 on endometrial cancer \[[@R35], [@R37], [@R38]\], and 2 on ovarian cancer \[[@R30], [@R31]\]. The ethnic group was Asian in 7 studies and Non-Asian in 8 studies. Of the 5 studies related to rs25489, all focused on cervical cancer. The population was Asian in 4 studies and Non-Asian in one study.

Across all studies, the distribution of genotypes in controls was mostly in agreement with Hardy-Weinberg equilibrium (HWE), except in 5 studies on rs25487 \[[@R6], [@R15], [@R17], [@R18], [@R36]\], 5 studies on rs1799782 \[[@R15]--[@R18], [@R26]\] and 2 studies on rs25489 \[[@R15], [@R39]\].

Quantitative data synthesis {#s2_2}
---------------------------

Across the entire pooled study population, a significant association was not found between rs25487 and risk of female reproductive system cancer (Table [2](#T2){ref-type="table"}). In the subgroup of Asian participants, however, we detected a significant association of the A variant at rs25487 with increased risk of female reproductive system cancer (GA vs. GG, OR 1.16, 95%CI 1.00--1.36). This association disappeared when we excluded 5 studies that deviated from HWE, instead appearing in the subgroup of Non-Asian participants (AA vs. GA/GG, OR 1.61, 95%CI 1.41--1.85). Subgroup analysis by cancer type indicated an association between the A allele at rs25487 and increased risk of cervical cancer (AA vs. GA/GG, OR 1.22, 95%CI 1.05--1.41), endometrial cancer (AA vs. GG, OR 2.16, 95%CI 1.00--4.67) and ovarian cancer (AA vs. GA/GG, OR 2.01, 95%CI 1.70--2.38). The significant associations with cervical cancer and ovarian cancer disappeared after removing studies that deviated from HWE.

###### Meta-analysis of the associations between XRCC1 polymorphisms and risk of female reproductive system cancer

  Variable                           *N*         Cases/controls   Homozygous genetic model   Heterozygous genetic model   Dominant genetic model   Recessive genetic model                                                                             
  ---------------------------------- ----------- ---------------- -------------------------- ---------------------------- ------------------------ ------------------------- ------- ------ ----------------- ------- ------ ----------------- ------- ------
  ***rs25487 (Arg399Gln)***          AA vs. GG   GA vs. GG        (AA+GA) vs. GG             AA vs. (GA+GG)                                                                                                                                            
  All studies                        24          4265/5495        1.34(0.92,1.97)            0.000                        81.6                     1.06(0.92,1.22)           0.001   54.4   1.11(0.95,1.31)   0.000   67.2   1.32(0.89,1.95)   0.000   85.1
  Ethnicity                                                                                                                                                                                                                                            
   Asian                             11          2185/3208        1.49(0.90,2.45)            0.000                        73.6                     1.16(1.00,1.36)           0.121   34.7   1.19(0.99,1.42)   0.014   55.1   1.41(0.87,2.27)   0.000   72.8
   Non-Asian                         13          2080/2287        1.24(0.68,2.24)            0.000                        86.5                     0.96(0.76,1.22)           0.004   59.7   1.03(0.79,1.36)   0.000   73.5   1.26(0.68,2.32)   0.000   89.9
  Tumor type                                                                                                                                                                                                                                           
   Cervical                          16          3146/4066        1.36(0.87,2.12)            0.000                        80.5                     1.10(0.93,1.30)           0.000   58.5   1.11(0.92,1.33)   0.000   68.6   1.22(1.05,1.41)   0.000   79.0
   Endometrial                       5           895/983          2.16(1.00,4.67)            0.006                        72                       1.02(0.67,1.53)           0.022   65.1   1.37(0.92,2.03)   0.016   67.0   0.68(0.43,1.07)   0.000   84.1
   Ovarian                           3           224/446          0.63(0.21,1.93)            0.026                        72.5                     0.92(0.65,1.31)           0.921   0.0    0.80(0.51,1.25)   0.186   40.6   2.01(1.70,2.38)   0.025   72.8
  Consistent with HWE                19          3595/4742        1.35(0.94,1.92)            0.000                        75.6                     1.07(0.90,1.27)           0.000   63.7   1.16(0.97,1.38)   0.000   68.5   1.31(0.90,1.91)   0.000   81.6
   Asian                             9           1850/2758        1.17(0.76,1.80)            0.009                        60.7                     1.18(0.99,1.42)           0.073   44.2   1.16(0.94,1.44)   0.005   63.9   1.10(0.76,1.62)   0.036   51.5
   Non-Asian                         10          1745/1984        1.59(0.90,2.80)            0.000                        83.1                     0.97(0.72,1.30)           0.001   69.7   1.15(0.85,1.56)   0.000   73.7   1.61(1.41,1.85)   0.000   87.9
  Tumor type (consistent with HWE)                                                                                                                                                                                                                     
   Cervical                          12          2526/3391        1.17(0.80,1.71)            0.000                        69.6                     1.11(0.90,1.38)           0.000   69.3   1.11(0.89,1.39)   0.000   73.5   1.10(0.93,1.30)   0.010   56.7
   Endometrial                       5           895/983          2.16(1.00,4.67)            0.006                        72.0                     1.02(0.67,1.53)           0.022   65.1   1.37(0.92,2.03)   0.016   67.0   0.68(0.43,1.07)   0.000   84.1
   Ovarian                           2           560/368          1.04(0.55,1.99)            0.582                        0.0                      0.95(0.64,1.41)           0.950   0.0    0.97(0.67,1.40)   0.907   0.0    1.06(0.61,1.84)   0.557   0.0
  ***rs1799782 (Arg194Trp)***        TT vs. CC   CT vs. CC        (TT+CT) vs. CC             TT vs. (CT+CC)                                                                                                                                            
  All studies                        15          2672/3578        1.19(0.67,2.13)            0.000                        84.7                     1.02(0.84,1.23)           0.011   52.5   0.93(0.71,1.21)   0.000   77.1   1.19(0.71,1.98)   0.000   82.5
  Ethnicity                                                                                                                                                                                                                                            
   Asian                             7           1279/2007        2.30(1.39,3.82)            0.016                        61.4                     1.16(0.99,1.34)           0.588   0.0    1.28(1.10,1.50)   0.348   10.7   2.11(1.33,3.34)   0.031   56.9
   Non-Asian                         8           1393/1571        0.42(0.14,1.26)            0.000                        83.5                     0.76(0.48,1.19)           0.003   70.4   0.62(0.39,0.99)   0.000   75.7   0.46(0.20,1.10)   0.001   76.1
  Tumor type                                                                                                                                                                                                                                           
   Cervical                          10          1593/2125        1.20(0.50,2.87)            0.000                        88.7                     1.02(0.79,1.32)           0.008   61.4   0.96(0.68,1.36)   0.000   80.7   1.30(1.07,1.59)   0.000   86.6
   Endometrial                       3           185/365          2.50(1.16,5.37)            /                            /                        1.01(0.36,2.87)           0.079   67.5   1.06(0.34,3.31)   0.054   73.1   1.80(0.98,3.29)   /       /
   Ovarian                           2           894/1088         0.96(0.72,1.28)            0.789                        0.0                      0.93(0.62,1.38)           0.222   33.6   0.77(0.62,0.95)   0.755   0.0    0.91(0.77,1.09)   0.831   0.0
  Consistent with HWE                10          1938/2771        1.45(0.96,2.19)            0.017                        58.9                     1.08(0.91,1.28)           0.276   18.8   1.01(0.79,1.29)   0.009   58.7   1.35(0.90,2.02)   0.009   62.4
   Asian                             5           933/1539         1.67(1.33,2.09)            0.224                        29.6                     1.08(0.98,1.18)           0.311   16.3   1.12(1.04,1.21)   0.153   40.2   1.65(1.30,2.09)   0.403   0.6
   Non-Asian                         5           1005/1232        0.98(0.85,1.13)            0.782                        0.0                      1.00(0.92,1.10)           0.227   30.9   0.93(0.88,0.98)   0.504   0.0    0.91(0.77,1.09)   0.823   0.0
  Tumor type (consistent with HWE)                                                                                                                                                                                                                     
   Cervical                          5           859/1318         1.62(1.26,2.07)            0.156                        42.5                     1.06(0.95,1.17)           0.337   11.1   1.10(1.01,1.20)   0.243   26.8   1.63(1.26,2.11)   0.268   23.9
   Endometrial                       3           185/365          2.00(1.15,3.49)            /                            /                        1.12(0.89,1.41)           0.120   58.6   1.15(0.96,1.39)   0.110   60.9   1.80(0.98,3.29)   /       /
   Ovarian                           2           894/1088         0.98(0.85,1.13)            0.782                        0.0                      1.01(0.93,1.11)           0.257   26.5   0.93(0.88,0.99)   0.355   3.5    0.91(0.77,1.09)   0.823   0.0
  ***rs25489 (Arg280His)***          AA vs. GG   GA vs. GG        (AA+GA) vs. GG             AA vs. (GA+GG)                                                                                                                                            
  All studies                        5           907/1416         2.91(1.17,7.26)            0.067                        54.3                     0.98(0.80,1.21)           0.558   0.0    1.31(0.77,2.24)   0.000   80.5   3.16(1.91,5.24)   0.093   49.7
  Ethnicity                                                                                                                                                                                                                                            
   Asian                             4           842/1348         1.73(0.87,3.43)            0.524                        0.0                      0.97(0.82,1.15)           0.683   0.0    1.00(0.85,1.18)   0.546   0.0    1.74(0.88,3.45)   0.512   0.0
   Non-Asian                         1           65/68            3.10(1.85,5.20)            /                            /                        1.81(0.68,4.86)           /       /      2.35(1.57,3.52)   /       /      3.14(1.85,5.32)   /       /

N: Number of studies. P~het~: *P* value for heterogeneity test. HWE: Hardy--Weinberg equilibrium.

Across the entire pooled study population, no association was found between rs1799782 and risk of female reproductive system cancer (Table [2](#T2){ref-type="table"}). In subgroup analysis by ethnicity, the T variant was significantly associated with increased risk of female reproductive system cancer in Asians (TT vs. CC, OR 2.30, 95%CI 1.39--3.82; TT/CT vs. CC, OR 1.28, 95%CI 1.10--1.50; TT vs. CT/CC, OR 2.11, 95%CI 1.33--3.34). This association remained significant after excluding 5 studies that deviated from HWE(TT vs. CC, OR 1.67, 95%CI 1.33--2.09; TT/CT vs. CC, OR 1.12, 95%CI 1.04--1.21; TT vs. CT/CC, OR 1.65, 95%CI 1.30--2.09). In subgroup analysis by tumor type, the T allele was associated with increased risk of cervical cancer (TT vs. CT/CC, OR 1.30, 95%CI 1.07--1.59), and this association remained significant after excluding studies that deviated from HWE (TT vs. CC, OR 1.62, 95%CI 1.26--2.07; TT/CT vs. CC, OR 1.10, 95%CI 1.01--1.20; TT vs. CT/CC, OR 1.63, 95%CI 1.26--2.11). The same T variant increased risk of endometrial cancer based on all study participants (TT vs. CC, OR 2.50, 95%CI 1.16--5.37) as well as based on only studies consistent with HWE (TT vs. CC, OR 2.00, 95%CI 1.15--3.49).

Data on rs25489 SNPs were limited to cervical cancer studies. Meta-analysis suggested that the A variant was associated with increased risk of this cancer (AA vs. GG, OR 2.91, 95%CI 1.17--7.26; AA vs. GA/GG, OR 3.16, 95%CI 1.91--5.24).

Heterogeneity and sensitivity analyses {#s2_3}
--------------------------------------

Significant heterogeneity across studies was observed in the meta-analysis of the association between the A variant at rs25487 and risk of female reproductive system cancer (homozygous model, I^2^ = 81.6, *P* = 0.000; heterozygous model: I^2^ = 54.4, *P* = 0.001; dominant model: I^2^ = 67.2, *P* \< 0.001; recessive model: I^2^ = 85.1, *P* \< 0.001). Similarly, significant heterogeneity across studies was observed in the meta-analysis of the association between the T allele at rs1799782 and cancer risk (homozygous model, I^2^ = 84.7, *P* \< 0.001; heterozygous model, I^2^ = 52.5, *P* = 0.011; dominant model, I^2^ = 77.1, *P* \< 0.001; recessive model: I^2^ = 82.5, *P* \< 0.001). Among studies used in meta-analyses involving rs25489, we found moderate heterogeneity in the homozygous model (I^2^ = 54.3, *P* = 0.067) and dominant model (I^2^ = 80.5, *P* \< 0.001), but no significant heterogeneity in the heterozygous or recessive models.

Then we performed sensitivity analysis, in which we recalculated the meta-analysis after deleting each study systematically. The results were not substantially different after excluding any single study, indicating the robustness of our original meta-analyses.

DISCUSSION {#s3}
==========

XRCC1 is the first protein to participate in the BER pathway, acting as a scaffold for other DNA repair proteins, such as DNA ligase IIIa, DNA polymerase β and poly (ADP-ribose) polymerase \[[@R40]\]. The *XRCC1* SNPs rs25487, rs1799782, and rs25489 have been linked to susceptibility for several types of cancer, but it is unclear whether this is also true for female reproductive system cancer. The present meta-analysis suggests that as in other cancers, *XRCC1* polymorphism may also influence tumorigenesis in the female reproductive system.

The present study may be the first quantitative meta-analysis of *XRCC1* polymorphism and risk of female reproductive system cancer. Previous meta-analyses focused only on cervical cancer risk \[[@R41]--[@R45]\], and they reported that rs25487 and rs1799782 were associated with increased risk in Asian populations. The present meta-analysis extended this finding by showing that in Asians, the A allele of rs25487 and T allele of rs1799782 are associated with increased risk of female reproductive system cancer. These findings should be verified in larger studies, especially since the association with rs25487 disappeared in Asians and appeared in Non-Asians after we excluded studies deviating from HWE.

We did not observe a significant association between *XRCC1* rs25489 and risk of ovarian cancer, even though estrogens and their metabolites damage DNA by forming bulky DNA adducts \[[@R46]\], which are normally repaired by the BER pathway. It is possible that our negative results reflect limited sample size. Further studies are needed to verify our findings.

To ensure results as reliable as possible, we analogized the studies in our meta-analysis to approximate randomized controlled trials. At the same time, our study does have several limitations. Our results were based on OR analyses that did not adjust for age, family history, gender, reproductive history, or other biological factors that might influence risk of female reproductive system cancer. Similarly, we did not take into account potential effects of gene-environment interaction. Therefore further work is needed before definitive conclusions can be drawn about these three *XRCC1* SNPs and risk of female reproductive system cancer.

Despite these limitations, our data provide up-to-date evidence from a comprehensive review of the literature that the A allele of rs25487 and T allele of rs1799782 are low-penetration risk factors for female reproductive system cancer in Asians. It may be that these alleles translate to weaker interaction between XRCC1 and other repair proteins, thereby reducing DNA repair capacity \[[@R47]\]. Our findings add to the growing evidence that polymorphism in DNA repair genes can destabilize the genome and increase tumor susceptibility \[[@R32]\].

MATERIALS AND METHODS {#s4}
=====================

Literature search strategy {#s4_1}
--------------------------

We performed a comprehensive literature search in the PubMed, EMBASE, Scopus, and CNKI databases up to December 17, 2016. The following search strings were used: "X-ray repair cross complementing protein1" or "XRCC1"; "polymorphisms" or "variants"; "carcinoma" or "cancer" or "malignancy" or "neoplasm" or "tumour" or "tumor"; "cervical" or "endometrial" or "ovarian" or "vaginal" or "vulvar" or "fallopian tube" or "female reproductive system". The reference lists of relevant articles were also searched manually to identify additional eligible studies. When different studies presented overlapping data, we included only the larger study.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Studies included in this meta-analysis had to be case-control or genome-wide association studies for which full text was available and that reported adequate data on genotype frequencies for cases and controls. Studies were excluded if they reported data overlapping with those of a larger study.

Data extraction {#s4_3}
---------------

Two investigators (N.-N.Y and Y.-F.H) independently extracted the following data from all eligible publications: the first author\'s name, year of publication, country of origin, ethnicity, study type (retrospective or prospective), source of control subjects (population-based \[PB\] or hospital-based \[HB\]), DNA source (*e.g*., blood, lymphocytes or buffy coat), genotyping method, total numbers of cases and controls and *P value* for HWE. Conflicts were resolved by consensus among all authors.

Statistical analysis {#s4_4}
--------------------

Agreement between study results and HWE predictions was tested using the goodness-of-fit χ^2^ test, with the threshold for HWE defined as *P* \> 0.05. Strength of association between *XRCC1* SNPs and cancer risk was assessed using odds ratios (ORs) and associated 95% confidence intervals (95%CI). Four different genetic models were conducted to detect the association: homozygous model (VV vs. WW), heterozygous model (WV vs. WW), dominant genetic model (VV+WV vs. WW) and recessive model (VV vs. WW+WV), with W and V representing the wild and variant alleles of each SNP. Heterogeneity across studies was assessed using a χ^2^-test-based *Q* statistic test, and the level of heterogeneity was quantified using the I^2^ test. When heterogeneity across studies was obvious (*P* ≥ 0.05 or I^2^ \< 50%) \[[@R48]\], the random effects model was used to meta-analyze data from different studies. Otherwise, the fixed effects model was adopted \[[@R49]\]. All studies were analogized into interim randomized controlled clinical trials in order to control for type I and type II error.

Subgroup analyses were carried out based on ethnicity, tumor type and HWE \[[@R50]\]. Sensitivity analysis was performed in which we recalculated the meta-analysis after deleting each study systematically. Publication bias was investigated using Begg\'s and Egger\'s test \[[@R51]\], with significant risk of bias defined as *P* \< 0.05. All statistical analyses were performed using STATA 11.0 (Stata Corp, College Station, Texas USA). All *P* values were two-sided.
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